MRSA drug receives preliminary approval from FDA panel
Patient Safety Monitor Alert
January 7, 2009
The Food and Drug Administration's Anti-Infective Drugs Advisory Committee has given preliminary approval for a new medication, telavancin, for preventing methicillin-resistant Staphylococcus aureus (MRSA), reports American Medical News. Two other drugs that were up for approval for combating infections caused by MRSA were not approved by this committee. The need for some type of drug that prevents the spread of MRSA and other bacteria is becoming more necessary as many of these bacteria are growing resistant to the drugs that are available for physicians to prescribe.
MRSA infection rates are climbing at a steady rate, with 94,000 infections in the United States in 2004, reported by the Journal of the American Medical Association.
To read more, click here.
